536 related articles for article (PubMed ID: 21781227)
61. Effects of treatment with androgen receptor ligands on microRNA expression of prostate cancer cells.
Segal CV; Koufaris C; Powell C; Gooderham NJ
Toxicology; 2015 Jul; 333():45-52. PubMed ID: 25846647
[TBL] [Abstract][Full Text] [Related]
62. Different profiles of neuroendocrine cell differentiation evolve in the PC-310 human prostate cancer model during long-term androgen deprivation.
Jongsma J; Oomen MH; Noordzij MA; Van Weerden WM; Martens GJ; van der Kwast TH; Schröder FH; van Steenbrugge GJ
Prostate; 2002 Mar; 50(4):203-15. PubMed ID: 11870798
[TBL] [Abstract][Full Text] [Related]
63. Cytology of metastatic prostate cancer following orchiectomy and antiandrogen therapy: a diagnostic challenge.
Rapkiewicz A; Gorokhovsky R; Farcon E; Das K
Diagn Cytopathol; 2008 Jul; 36(7):499-502. PubMed ID: 18528888
[TBL] [Abstract][Full Text] [Related]
64. PI3K/Akt signaling regulates p27(kip1) expression via Skp2 in PC3 and DU145 prostate cancer cells, but is not a major factor in p27(kip1) regulation in LNCaP and PC346 cells.
van Duijn PW; Trapman J
Prostate; 2006 May; 66(7):749-60. PubMed ID: 16425184
[TBL] [Abstract][Full Text] [Related]
65. Preferential induction of G1 arrest in androgen-responsive human prostate cancer cells by androgen receptor signaling antagonists DL3 and antiandrogen bicalutamide.
Lu S; Tan Z; Wortman M; Lu S; Dong Z
Cancer Lett; 2010 Dec; 298(2):250-7. PubMed ID: 20675041
[TBL] [Abstract][Full Text] [Related]
66. CSL regulates AKT to mediate androgen independence in prostate cancer progression.
Wang H; Zhang L; Fu Y; Fang F; Jiang Y; Dong Y; Zhu W
Prostate; 2016 Feb; 76(2):140-50. PubMed ID: 26437743
[TBL] [Abstract][Full Text] [Related]
67. Androgen receptor-mTOR crosstalk is regulated by testosterone availability: implication for prostate cancer cell survival.
Wu Y; Chhipa RR; Cheng J; Zhang H; Mohler JL; Ip C
Anticancer Res; 2010 Oct; 30(10):3895-901. PubMed ID: 21036700
[TBL] [Abstract][Full Text] [Related]
68. HEXIM1 plays a critical role in the inhibition of the androgen receptor by anti-androgens.
Yeh IJ; Song K; Wittmann BM; Bai X; Danielpour D; Montano MM
Biochem J; 2014 Sep; 462(2):315-27. PubMed ID: 24844355
[TBL] [Abstract][Full Text] [Related]
69. Zyflamend inhibits the expression and function of androgen receptor and acts synergistically with bicalutimide to inhibit prostate cancer cell growth.
Yan J; Xie B; Capodice JL; Katz AE
Prostate; 2012 Feb; 72(3):244-52. PubMed ID: 21656835
[TBL] [Abstract][Full Text] [Related]
70. Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells.
Gravina GL; Festuccia C; Millimaggi D; Dolo V; Tombolini V; de Vito M; Vicentini C; Bologna M
Prostate; 2008 May; 68(7):793-801. PubMed ID: 18324645
[TBL] [Abstract][Full Text] [Related]
71. Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells.
Sadar MD; Gleave ME
Cancer Res; 2000 Oct; 60(20):5825-31. PubMed ID: 11059779
[TBL] [Abstract][Full Text] [Related]
72. Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: pro-apoptotic effects and underlying mechanisms.
De Petrocellis L; Ligresti A; Schiano Moriello A; Iappelli M; Verde R; Stott CG; Cristino L; Orlando P; Di Marzo V
Br J Pharmacol; 2013 Jan; 168(1):79-102. PubMed ID: 22594963
[TBL] [Abstract][Full Text] [Related]
73. Prosaposin upregulates AR and PSA expression and activity in prostate cancer cells (LNCaP).
Koochekpour S; Lee TJ; Wang R; Culig Z; Delorme N; Caffey S; Marrero L; Aguirre J
Prostate; 2007 Feb; 67(2):178-89. PubMed ID: 17044040
[TBL] [Abstract][Full Text] [Related]
74. 5-Azacitidine restores and amplifies the bicalutamide response on preclinical models of androgen receptor expressing or deficient prostate tumors.
Gravina GL; Marampon F; Di Staso M; Bonfili P; Vitturini A; Jannini EA; Pestell RG; Tombolini V; Festuccia C
Prostate; 2010 Aug; 70(11):1166-78. PubMed ID: 20333699
[TBL] [Abstract][Full Text] [Related]
75. Growth Inhibition by Testosterone in an Androgen Receptor Splice Variant-Driven Prostate Cancer Model.
Nakata D; Nakayama K; Masaki T; Tanaka A; Kusaka M; Watanabe T
Prostate; 2016 Dec; 76(16):1536-1545. PubMed ID: 27473672
[TBL] [Abstract][Full Text] [Related]
76. Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer.
Liu C; Armstrong CM; Lou W; Lombard AP; Cucchiara V; Gu X; Yang JC; Nadiminty N; Pan CX; Evans CP; Gao AC
Mol Cancer Ther; 2017 Aug; 16(8):1521-1530. PubMed ID: 28500234
[TBL] [Abstract][Full Text] [Related]
77. Antitumor effects of carnertinib in castration resistant prostate cancer models: a comparative study with erlotinib.
Gravina GL; Marampon F; Piccolella M; Biordi L; Ficorella C; Motta M; Jannini EA; Tombolini V; Festuccia C
Prostate; 2011 Oct; 71(14):1481-91. PubMed ID: 21446006
[TBL] [Abstract][Full Text] [Related]
78. PXD101 potentiates hormonal therapy and prevents the onset of castration-resistant phenotype modulating androgen receptor, HSP90, and CRM1 in preclinical models of prostate cancer.
Gravina GL; Marampon F; Muzi P; Mancini A; Piccolella M; Negri-Cesi P; Motta M; Lenzi A; Di Cesare E; Tombolini V; Jannini EA; Festuccia C
Endocr Relat Cancer; 2013 Jun; 20(3):321-37. PubMed ID: 23507703
[TBL] [Abstract][Full Text] [Related]
79. Androgen deprivation and androgen receptor competition by bicalutamide induce autophagy of hormone-resistant prostate cancer cells and confer resistance to apoptosis.
Boutin B; Tajeddine N; Vandersmissen P; Zanou N; Van Schoor M; Mondin L; Courtoy PJ; Tombal B; Gailly P
Prostate; 2013 Jul; 73(10):1090-102. PubMed ID: 23532738
[TBL] [Abstract][Full Text] [Related]
80. Androgen Receptor Expression and Bicalutamide Antagonize Androgen Receptor Inhibit β-Catenin Transcription Complex in Estrogen Receptor-Negative Breast Cancer.
Huang R; Han J; Liang X; Sun S; Jiang Y; Xia B; Niu M; Li D; Zhang J; Wang S; Wei W; Liu Q; Zheng W; Zhang G; Song Y; Panga D
Cell Physiol Biochem; 2017; 43(6):2212-2225. PubMed ID: 29069648
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]